CN1243740C - 乙酰替苯胺衍生物的α型或β型结晶 - Google Patents

乙酰替苯胺衍生物的α型或β型结晶 Download PDF

Info

Publication number
CN1243740C
CN1243740C CNB02821370XA CN02821370A CN1243740C CN 1243740 C CN1243740 C CN 1243740C CN B02821370X A CNB02821370X A CN B02821370XA CN 02821370 A CN02821370 A CN 02821370A CN 1243740 C CN1243740 C CN 1243740C
Authority
CN
China
Prior art keywords
type
crystallization
ethyl
amino
phenylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB02821370XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1575287A (zh
Inventor
川添聪一郎
坂元健一郎
粟村勇治
丸山龙也
铃木贵之
恩田健一
高须俊行
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Astellas Pharma Inc
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19148268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1243740(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Yamanouchi Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of CN1575287A publication Critical patent/CN1575287A/zh
Application granted granted Critical
Publication of CN1243740C publication Critical patent/CN1243740C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CNB02821370XA 2001-10-30 2002-10-29 乙酰替苯胺衍生物的α型或β型结晶 Expired - Lifetime CN1243740C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001332914 2001-10-30
JP332914/2001 2001-10-30

Publications (2)

Publication Number Publication Date
CN1575287A CN1575287A (zh) 2005-02-02
CN1243740C true CN1243740C (zh) 2006-03-01

Family

ID=19148268

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02821370XA Expired - Lifetime CN1243740C (zh) 2001-10-30 2002-10-29 乙酰替苯胺衍生物的α型或β型结晶

Country Status (17)

Country Link
US (2) US7342117B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2298752B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3800220B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100908796B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1243740C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2002344419C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0213570B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2464068C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2404071T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU230481B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04003936A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO326965B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL218982B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2303033C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW200300020A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003037881A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200403044B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
DK1559427T3 (da) 2002-11-07 2011-04-26 Astellas Pharma Inc Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2009057685A1 (ja) * 2007-11-02 2009-05-07 Astellas Pharma Inc. 過活動膀胱治療用医薬組成物
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2665467T3 (es) * 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
EP2583967B1 (en) * 2010-06-16 2014-10-01 Takeda Pharmaceutical Company Limited Crystal of amide compound
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
EP2709993A4 (en) * 2011-05-18 2015-02-25 Reddys Lab Ltd Dr AMORPHIC MIRABEGRON AND METHOD FOR CRYSTALLINE FORMS OF MIRABEGRON
WO2013063512A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20150031734A1 (en) 2012-03-30 2015-01-29 Astellas Pharma Inc. Pharmaceutical composition containing mirabegron
CN103387500A (zh) * 2012-05-11 2013-11-13 上海医药工业研究院 一种米拉贝隆及其中间体的制备方法
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JPWO2014034860A1 (ja) 2012-08-31 2016-08-08 アステラス製薬株式会社 経口投与用医薬組成物
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (it) 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103641792B (zh) * 2013-12-27 2015-07-22 国药集团国瑞药业有限公司 一种米拉贝隆有关物质或其盐、其制备方法和用途
CN104876889B (zh) * 2014-02-27 2017-02-22 人福医药集团股份公司 化合物的合成方法
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
CN103896872A (zh) * 2014-04-29 2014-07-02 黑龙江大学 米拉贝隆的合成方法
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
ES2676586T3 (es) * 2014-08-06 2018-07-23 Interquim, S.A. Procedimiento para la síntesis de mirabegron y sus derivados
WO2016024284A2 (en) 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN105481705A (zh) * 2014-08-23 2016-04-13 南京海纳医药科技有限公司 (r)-2-[[2-(4-氨基苯基)乙基]氨基]-1-苯乙醇的制备及应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
US10149837B2 (en) 2014-09-26 2018-12-11 Universita' Degli Studi Di Bari Selective agonists of beta-adrenergic type 3 receptors (BAR3) and use thereof
CA2962664A1 (en) * 2014-10-01 2016-04-07 Apotex Inc. Solid forms of mirabegron
JP2018508497A (ja) 2015-02-02 2018-03-29 ルピン・リミテッド ミラベグロンの多形型の調製方法
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
FR3043555B1 (fr) * 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) Mirabegron pour le traitement de maladies retiniennes
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
CN105801438A (zh) * 2016-04-12 2016-07-27 济南大学 一种米拉贝隆中间体的合成方法
CN107963976A (zh) * 2016-10-20 2018-04-27 中国动物疫病预防控制中心 一种苯乙醇胺类化合物中间体的制备方法
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
SI3360866T1 (sl) 2017-02-14 2019-04-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Mirabegronska predzdravila
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
KR20200012949A (ko) 2017-06-06 2020-02-05 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
CN108658797A (zh) * 2018-06-19 2018-10-16 安徽德信佳生物医药有限公司 一种米拉贝隆中间体(r)-2-(4-硝基苯乙基氨基)-1-苯基乙醇盐酸盐的合成
CN108947853A (zh) * 2018-06-29 2018-12-07 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成米拉贝隆中间体的方法
KR101928987B1 (ko) * 2018-08-28 2018-12-13 (주) 성운파마코피아 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
CN113164486A (zh) 2018-12-05 2021-07-23 尤偌万科学有限公司 用于治疗膀胱过度活动症症状的维贝格龙
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
CN110590699B (zh) * 2019-09-29 2022-11-15 广东先强药业有限公司 一种米拉贝隆的精制方法
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
CN114539084B (zh) * 2020-11-24 2024-04-02 威智医药股份有限公司 米拉贝隆及其中间体的制备方法
CN114539182B (zh) * 2020-11-24 2024-08-09 威智医药股份有限公司 转晶溶剂及其应用和米拉贝隆α晶型的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
CN112574137A (zh) * 2021-01-19 2021-03-30 南京美瑞制药有限公司 一种α晶型米拉贝隆的制备方法
KR20240116208A (ko) 2023-01-20 2024-07-29 이니스트에스티 주식회사 결정형의 미라베그론 신규염, 이의 제조방법 및 이를 포함하는 약학적 조성물
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1921577B2 (de) * 1969-04-28 1972-04-06 Nixdorf Computer Ag, 4790 Paderborn Trommelartige vorrichtung zn buchungs- und schreibautomaten mit greifeinrichtung zum erfassen und einziehen von kontokarten o dgl
JPH02279685A (ja) 1989-04-18 1990-11-15 Yoshitomi Pharmaceut Ind Ltd 新規な結晶構造を有するチアジアジン化合物およびその製造法
US6048884A (en) * 1997-01-23 2000-04-11 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives and medicinal compositions thereof
ES2221204T3 (es) * 1997-10-17 2004-12-16 Yamanouchi Pharmaceutical Co. Ltd. Derivados de amidas o sales de los indicados derivados.
JP3901832B2 (ja) 1998-03-13 2007-04-04 大日本インキ化学工業株式会社 キノリノン誘導体製剤、及びその製造法
JP2000212168A (ja) 1999-01-22 2000-08-02 Yamanouchi Pharmaceut Co Ltd ヘキサヒドロ―１，４―ジアゼピン誘導体塩水和物の新規結晶
EP1129712A4 (en) * 1999-09-10 2002-11-05 Dainippon Ink & Chemicals PREPARATIONS BASED ON QUINOLINONE DERIVATIVES AND MANUFACTURING METHOD
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative

Also Published As

Publication number Publication date
JPWO2003037881A1 (ja) 2005-02-17
WO2003037881A1 (fr) 2003-05-08
BR0213570A (pt) 2004-10-26
JP3800220B2 (ja) 2006-07-26
TW200300020A (en) 2003-05-01
PL369874A1 (en) 2005-05-02
EP1440969A4 (en) 2005-01-19
TWI322805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-04-01
EP2298752B1 (en) 2013-03-27
US7982049B2 (en) 2011-07-19
AU2002344419B2 (en) 2007-12-13
EP1440969A1 (en) 2004-07-28
EP2298752A1 (en) 2011-03-23
US20050004190A1 (en) 2005-01-06
US20080214633A1 (en) 2008-09-04
CA2464068C (en) 2007-10-16
ZA200403044B (en) 2005-06-29
HUP0401665A1 (hu) 2004-11-29
CN1575287A (zh) 2005-02-02
NO326965B1 (no) 2009-03-23
BRPI0213570B1 (pt) 2018-02-27
EP1932838A2 (en) 2008-06-18
EP1932838A3 (en) 2008-07-30
AU2002344419C1 (en) 2024-02-01
HU230481B1 (hu) 2016-07-28
US7342117B2 (en) 2008-03-11
KR100908796B9 (ko) 2024-07-17
KR100908796B1 (ko) 2009-07-22
RU2303033C2 (ru) 2007-07-20
BRPI0213570B8 (pt) 2021-05-25
HUP0401665A3 (en) 2008-05-28
CA2464068A1 (en) 2003-05-08
MXPA04003936A (es) 2004-06-18
NO20042227L (no) 2004-05-28
RU2004116313A (ru) 2005-03-27
KR20050040837A (ko) 2005-05-03
ES2404071T3 (es) 2013-05-23
PL218982B1 (pl) 2015-02-27

Similar Documents

Publication Publication Date Title
CN1243740C (zh) 乙酰替苯胺衍生物的α型或β型结晶
AU2008215384B2 (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
CN1751056A (zh) 铁有机化合物、其应用及其制备方法
CN1615133A (zh) 卡维地洛的结晶固体及其制备方法
CN1898211A (zh) 喹啉化合物的晶形及其生产方法
TWI530501B (zh) 純化十字孢靈素之方法
CN1498216A (zh) 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法
CN104829467A (zh) 盐酸氨溴索二水化合物
CN105985252B (zh) 一种门冬氨酸鸟氨酸晶型iv及其制备方法
WO2007107354A1 (en) Rosiglitazone hydrochloride hemihydrate
WO2006025939A1 (en) Crystalline forms of 1,24(s)-dihydroxy vitamin d2
JP2025505824A (ja) ジペプチジルペプチダーゼ１阻害剤結晶多形体及びその製造方法と用途
WO2007016209A2 (en) Pure 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt and purification process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20060301

CX01 Expiry of patent term